TUBB3 and gastric cancer: In this study, we found TUBB3 was relatively lower expressed in the females (P = 0.026), patients with age < 57 years (P = 0.024) and family history of gastric cancer (P = 0.025), suggesting the above anti-microtubule chemotherapeutic agents should be recommended for these patients to obtain more benefits.